Ozempic’s most common side effects hit the gut: nausea, vomiting, diarrhea, and constipation. In a two-year clinical study, 82% of people taking semaglutide (the active ingredient in Ozempic) experienced mild to moderate gastrointestinal problems, compared with 54% on placebo. But beyond the well-known stomach issues, Ozempic carries rarer and more serious risks that are worth understanding before you start or continue treatment.
Nausea, Vomiting, and Diarrhea
Digestive side effects are by far the most frequent complaint. Nausea tends to be worst during the first weeks on the drug and again each time your dose increases. The standard approach is to start at a low dose (0.25 mg per week) and increase no sooner than every four weeks, giving your body time to adjust. Many people find the nausea fades after several weeks at a stable dose.
Vomiting and diarrhea follow a similar pattern, peaking around dose changes and improving over time. These symptoms are usually mild to moderate, but for some people they’re severe enough to interfere with daily life. In clinical trials, severe gastrointestinal reactions occurred in up to 0.8% of participants on the higher dose. If you can’t keep food or fluids down for more than 24 to 36 hours, that’s a signal to contact your prescriber, because prolonged dehydration from vomiting can trigger more dangerous complications.
Gastroparesis (Delayed Stomach Emptying)
Ozempic works partly by slowing how fast your stomach empties, which helps you feel full longer. In some people, this effect goes too far and the stomach essentially stalls. That condition, gastroparesis, causes persistent nausea, bloating, vomiting of undigested food, and abdominal pain that can significantly reduce quality of life.
A large retrospective study published in BMJ Open Gastroenterology tracked over 55,000 people treated for obesity. Those on semaglutide developed gastroparesis at a rate of 6.5 per 1,000 person-years, compared with 2.1 per 1,000 for an alternative weight-loss medication and 1.1 per 1,000 for weight-loss surgery. After adjusting for other health factors, semaglutide users had roughly three times the gastroparesis risk compared to those on the alternative drug. That’s still a low absolute number, but it represents a meaningful increase in relative risk.
The FDA’s updated prescribing information for Ozempic now lists ileus (a temporary halt in bowel movement), intestinal obstruction, and severe constipation including fecal impaction as postmarketing adverse events. These are rare but serious complications that require medical attention.
Acute Pancreatitis
Pancreatitis, or inflammation of the pancreas, is listed as an uncommon side effect of Ozempic, occurring in somewhere between 1 in 1,000 and 1 in 100 users. The hallmark symptom is severe upper abdominal pain that radiates to the back, often accompanied by nausea and vomiting. It typically requires emergency hospital evaluation, including blood tests and imaging.
If pancreatitis is confirmed, Ozempic must be stopped permanently. People with a history of pancreatitis were excluded from semaglutide clinical trials, so there’s limited data on how the drug behaves in that group. If you’ve had pancreatitis before, your prescriber will likely consider this a significant red flag.
Gallbladder Problems
Rapid weight loss from any cause raises the risk of gallstones, and Ozempic is no exception. Gallstones can block the bile duct, causing sudden, intense pain in the upper right abdomen, nausea, and sometimes fever. The estimated frequency is roughly 1 in a few hundred patients. Some cases require surgery to remove the gallbladder. The risk appears to be tied more to the speed of weight loss than to the drug itself, but it’s still something to be aware of, especially in the first several months of treatment when weight loss tends to be fastest.
Kidney Injury From Dehydration
Several thousand cases of acute kidney injury linked to GLP-1 drugs like Ozempic are reported each year. About 45% of those cases require hospitalization, and roughly 4% result in death. The kidney damage is rarely caused by the drug directly. Instead, it’s a downstream effect of severe vomiting and dehydration. When you’re not keeping fluids down, your kidneys don’t get the blood flow they need and can be damaged quickly.
This risk is highest when you first start the medication or step up to a higher dose, which is exactly when nausea and vomiting tend to peak. Staying hydrated is critical. If you find yourself unable to eat or drink for a full day, that warrants a call to your healthcare provider before kidney function is compromised.
Thyroid Tumor Risk
Ozempic carries the FDA’s most prominent safety alert, a boxed warning, about a rare type of thyroid cancer called medullary thyroid carcinoma (MTC). In animal studies, semaglutide caused thyroid C-cell tumors in rodents. Whether this translates to humans isn’t fully established, but out of caution, Ozempic is contraindicated for anyone with a personal or family history of MTC or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
If you notice a lump in your neck, difficulty swallowing, hoarseness, or shortness of breath, those symptoms should be evaluated promptly. The risk appears to be very low in the general population, but the severity of the potential outcome is why it earned the boxed warning.
Vision Changes in People With Diabetes
One major clinical trial (SUSTAIN-6) found that semaglutide was associated with worsening diabetic retinopathy, including bleeding in the eye and decreased vision, at a rate 1.76 times higher than placebo. This led to a warning on the Ozempic label about potential vision changes.
However, more recent real-world data paints a less alarming picture. A Cleveland Clinic study of nearly 1,000 people with type 2 diabetes found that only 2.3% of those on GLP-1 drugs had retinopathy that developed or progressed, compared with 2.8% on a different class of blood sugar-lowering medication. After statistical adjustment, there was no significant association between GLP-1 drugs and worsening retinopathy. The initial trial results may have been related to how quickly blood sugar dropped rather than the drug itself, since rapid improvements in blood sugar control are known to temporarily worsen existing eye disease. If you have diabetic retinopathy, your eye doctor should be in the loop when you start Ozempic.
Low Blood Sugar With Other Diabetes Medications
Ozempic alone rarely causes dangerously low blood sugar. The risk changes significantly if you’re also taking insulin or certain oral diabetes medications that directly stimulate insulin production. Combining these drugs with Ozempic can push blood sugar too low, causing shakiness, confusion, sweating, and in severe cases, loss of consciousness. Your prescriber may need to reduce the dose of your other diabetes medications when adding Ozempic.
How the Side Effect Profile Changes Over Time
Most people experience the worst side effects during the first few months, particularly around dose increases. The gradual dose escalation schedule exists specifically to reduce this. Starting at 0.25 mg per week and stepping up by small increments every four weeks or longer gives your digestive system time to adapt. Many people who push through the initial weeks find that nausea and other GI symptoms become manageable or disappear entirely.
The serious complications (pancreatitis, kidney injury, gallbladder disease, gastroparesis) can occur at any point during treatment, not just at the beginning. Persistent or worsening abdominal pain, inability to keep food down, or symptoms that change character rather than improve deserve prompt medical evaluation rather than a wait-and-see approach.